Literature DB >> 18721791

Compound C inhibits clonal expansion of preadipocytes by increasing p21 level irrespectively of AMPK inhibition.

Minwoo Nam1, Woo Hyung Lee, Eun Ju Bae, Sang Geon Kim.   

Abstract

AMP-activated protein kinase (AMPK) activation inhibits adipocyte differentiation. This study investigated the effect of compound C (CC), a widely used AMPK inhibitor, on differentiation of 3T3-L1 preadipocytes. CC treatment blocked hormone-induced preadipocyte differentiation due to inhibition of mitotic clonal expansion, which was accompanied by the failure of degradation of p21, a cyclin-dependent kinase inhibitor. CC increased the level of p21 protein, but not its mRNA, in preadipocytes incubated in a hormone-free medium. Cycloheximide decreased the basal p21 level, which was inhibited by CC treatment, supporting the stabilization of p21 by CC. Treatment of AICAR or metformin, AMPK activators, failed to induce p21 or inhibit the ability of CC to increase p21 level. In conclusion, CC inhibits proliferation of preadipocytes as a consequence of an increase in p21 content, which might result from p21 stabilization, and the increase in p21 level by CC might not be associated with AMPK inhibition.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18721791     DOI: 10.1016/j.abb.2008.07.029

Source DB:  PubMed          Journal:  Arch Biochem Biophys        ISSN: 0003-9861            Impact factor:   4.013


  26 in total

1.  Compound C stimulates heme oxygenase-1 gene expression via the Nrf2-ARE pathway to preserve human endothelial cell survival.

Authors:  Xiao-Ming Liu; Kelly J Peyton; Ahmad R Shebib; Hong Wang; William Durante
Journal:  Biochem Pharmacol       Date:  2011-05-24       Impact factor: 5.858

Review 2.  AMPK inhibition in health and disease.

Authors:  Benoit Viollet; Sandrine Horman; Jocelyne Leclerc; Louise Lantier; Marc Foretz; Marc Billaud; Shailendra Giri; Fabrizio Andreelli
Journal:  Crit Rev Biochem Mol Biol       Date:  2010-08       Impact factor: 8.250

3.  Compound C inhibits vascular smooth muscle cell proliferation and migration in an AMP-activated protein kinase-independent fashion.

Authors:  Kelly J Peyton; Yajie Yu; Benjamin Yates; Ahmad R Shebib; Xiao-ming Liu; Hong Wang; William Durante
Journal:  J Pharmacol Exp Ther       Date:  2011-05-12       Impact factor: 4.030

4.  Differential regulation of p21 (waf1) protein half-life by DNA damage and Nutlin-3 in p53 wild-type tumors and its therapeutic implications.

Authors:  Li-Ju Chang; Alan Eastman
Journal:  Cancer Biol Ther       Date:  2012-07-24       Impact factor: 4.742

5.  Ambivalent effects of compound C (dorsomorphin) on inflammatory response in LPS-stimulated rat primary microglial cultures.

Authors:  Krzysztof Labuzek; Sebastian Liber; Bozena Gabryel; Lukasz Bułdak; Bogusław Okopień
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2009-11-26       Impact factor: 3.000

6.  Genetic disruption of AMPK signaling abolishes both contraction- and insulin-stimulated TBC1D1 phosphorylation and 14-3-3 binding in mouse skeletal muscle.

Authors:  Christian Pehmøller; Jonas T Treebak; Jesper B Birk; Shuai Chen; Carol Mackintosh; D Grahame Hardie; Erik A Richter; Jørgen F P Wojtaszewski
Journal:  Am J Physiol Endocrinol Metab       Date:  2009-06-16       Impact factor: 4.310

7.  AMP-activated protein kinase mediates the interferon-gamma-induced decrease in intestinal epithelial barrier function.

Authors:  Michael Scharl; Gisela Paul; Kim E Barrett; Declan F McCole
Journal:  J Biol Chem       Date:  2009-08-04       Impact factor: 5.157

8.  Latanoprost effectively ameliorates glucose and lipid disorders in db/db and ob/ob mice.

Authors:  Gaihong Wang; Xing Xu; Xingang Yao; Zhiyuan Zhu; Liang Yu; Lili Chen; Jing Chen; Xu Shen
Journal:  Diabetologia       Date:  2013-08-29       Impact factor: 10.122

9.  AMP-activated protein kinase selectively inhibited by the type II inhibitor SBI-0206965.

Authors:  Toby A Dite; Christopher G Langendorf; Ashfaqul Hoque; Sandra Galic; Richard J Rebello; Ashley J Ovens; Lisa M Lindqvist; Kevin R W Ngoei; Naomi X Y Ling; Luc Furic; Bruce E Kemp; John W Scott; Jonathan S Oakhill
Journal:  J Biol Chem       Date:  2018-04-25       Impact factor: 5.157

10.  Substituted oxindol-3-ylidenes as AMP-activated protein kinase (AMPK) inhibitors.

Authors:  Christopher J Matheson; Kimberly A Casalvieri; Donald S Backos; Mohammed Minhajuddin; Craig T Jordan; Philip Reigan
Journal:  Eur J Med Chem       Date:  2020-04-16       Impact factor: 6.514

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.